To evaluate the role of neoadjuvant chemotherapy in the final treatment plan and its impact on survival in bladder cancer patients who were diagnosed with variant histology in the radical cystectomy specimen and whose diagnostic accuracy was achieved with the previous transurethral resection of the bladder specimen.

Methods

In this retrospective multicenter study, data from 221 patients across 9 centers were analyzed between January 2012 and January 2022. The primary endpoint was overall, cancer-specific, recurrence-free, and metastasis-free survival rates among patients with and without neoadjuvant chemotherapy, and the secondary endpoint was to identify independent predictors of survival. The Kaplan–Meier method was used to estimate overall survival, cancer-specific survival, recurrence-free survival, and metastasis-free survival, and multivariate analyses were performed using the Cox-regression model.

Results

Kaplan–Meier estimates of overall, cancer-specific, recurrence-free, and metastasis-free survival demonstrated no significant difference between two groups. Cox multifactorial analysis revealed that the age (HR 1.030, 95% CI 1.003–1.057, p = 0.027), presence of pT4 tumor stage (HR 3.861, 95% CI 1.303–11.494, p = 0.015), and pN+ (HR 2.288, 95% CI 1.475–3.550, p < 0.001) at radical cystectomy histopathology were independent predictors of overall survival; presence of pT4 tumor stage and pN+ at radical cystectomy histopathology were independent predictors of cancer-specific survival (HR 8.245, 95% CI 1.873–36.292, p = 0.005 and HR 1.792, 95% CI 1.049–3.061, p = 0.033) and metastasis-free survival (HR 9.957, 95% CI 1.286–77.073, p = 0.028 and HR 2.949, 95% CI 1.674–5.197, p < 0.001); and the age (HR 1.047, 95% CI 1.006–1.090, p = 0.025) and pN+ at radical cystectomy histopathology (HR 4.150, 95% CI 1.917–8.981, p < 0.001) were independent predictors of recurrence-free survival.

Conclusion

Neoadjuvant chemotherapy does not provide any survival advantage in variant histology; therefore, considering the disadvantages, such as delaying radical cystectomy, which can lead to inadvertent disease progression and chemotherapy-related toxicities, cautious should be exercised when administering neoadjuvant chemotherapy.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflict of interest.

Supporting Information

REFERENCES

1Mori K, Abufaraj M, Mostafaei H, Quhal F, Karakiewicz PI, Briganti A, et al. A systematic review and meta-analysis of variant histology in urothelial carcinoma of the bladder treated with radical cystectomy. J Urol. 2020; 204: 1129–1140.
10.1097/JU.0000000000001305
PubMed Web of Science® Google Scholar
2Sanguedolce F, Calò B, Mancini V, Zanelli M, Palicelli A, Zizzo M, et al. Non-muscle invasive bladder cancer with variant histology: biological features and clinical implications. Oncology. 2021; 99: 345–358.
10.1159/000514759
PubMed Google Scholar
3Lonati C, Baumeister P, Ornaghi PI, Di Trapani E, De Cobelli O, Rink M, et al. Accuracy of transurethral resection of the bladder in detecting variant histology of bladder cancer compared with radical cystectomy. Eur Urol Focus. 2022; 8: 457–464.
10.1016/j.euf.2021.04.005
PubMed Web of Science® Google Scholar
4Lobo N, Shariat SF, Guo CC, Fernandez MI, Kassouf W, Choudhury A, et al. What is the significance of variant histology in urothelial carcinoma? Eur Urol Focus. 2020; 6: 653–663.
10.1016/j.euf.2019.09.003
PubMed Google Scholar
5Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, et al. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis. Oncologist. 2016; 21: 708–715.
10.1634/theoncologist.2015-0440
CAS PubMed Web of Science® Google Scholar
6Lin-Brande M, Pearce SM, Ashrafi AN, Nazemi A, Burg ML, Ghodoussipour S, et al. Assessing the impact of time to cystectomy for variant histology of urothelial bladder cancer. Urology. 2019; 133: 157–163.
10.1016/j.urology.2019.07.034
PubMed Google Scholar
7Hanna N, Trinh QD, Seisen T, Vetterlein MW, Sammon J, Preston MA, et al. Effectiveness of Neoadjuvant chemotherapy for muscle-invasive bladder cancer in the current real world setting in the USA. Eur Urol Oncol. 2018; 1: 83–90.
10.1016/j.euo.2018.03.001
PubMed Web of Science® Google Scholar
8Vetterlein MW, Wankowicz SAM, Seisen T, Lander R, Löppenberg B, Chun FK, et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer. 2017; 123: 4346–4355.
10.1002/cncr.30907
CAS PubMed Web of Science® Google Scholar
9Zaid HB, Patel SG, Stimson CJ, Resnick MJ, Cookson MS, Barocas DA, et al. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. Urology. 2014; 83: 75–80.
10.1016/j.urology.2013.07.072
PubMed Web of Science® Google Scholar
10Leite KRM, Borges LL, Filho LR, Chade D, Coelho RF, Cordeiro M, et al. Histological variants of urothelial carcinoma predict no response to neoadjuvant chemotherapy. Clin Genitourin Cancer. 2022; 20: e1–e6.
10.1016/j.clgc.2021.07.011
PubMed Google Scholar
11Pokuri VK, Syed JR, Yang Z, Field EP, Cyriac S, Pili R, et al. Predictors of complete pathologic response (pT0) to neoadjuvant chemotherapy in muscle-invasive bladder carcinoma. Clin Genitourin Cancer. 2016; 14: e59–e65.
10.1016/j.clgc.2015.09.013
PubMed Web of Science® Google Scholar
12Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, et al. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of southwest oncology group-directed intergroup study (S8710). BJU Int. 2011; 108: 693–699.
10.1111/j.1464-410X.2010.09900.x
CAS PubMed Web of Science® Google Scholar
13Lin J, Whalen M, Holder D, Hruby G, Decastro GJ, McKiernan J. Neoadjuvant chemotherapy in the treatment of muscle invasive bladder cancer with mixed histology. Can J Urol. 2013; 20: 6690–6695.
PubMed Web of Science® Google Scholar
14Mitra AP, Bartsch CC, Bartsch G Jr, Miranda G, Skinner EC, Daneshmand S. Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis. Urol Oncol. 2014; 32: 117–127.
10.1016/j.urolonc.2012.08.017
PubMed Web of Science® Google Scholar
15Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, et al. Pathological and survival outcomes associated with variant histology bladder cancers managed by cystectomy with or without neoadjuvant chemotherapy. J Urol. 2021; 205: 100–108.
10.1097/JU.0000000000001325
PubMed Google Scholar
16Matulay JT, Narayan VM, Kamat AM. Clinical and genomic considerations for variant histology in bladder cancer. Curr Oncol Rep. 2019; 21: 23.
10.1007/s11912-019-0772-8
PubMed Google Scholar
17Minato A, Fujimoto N, Kubo T. Squamous differentiation predicts poor response to cisplatin-based chemotherapy and unfavorable prognosis in urothelial carcinoma of the urinary bladder. Clin Genitourin Cancer. 2017; 15: e1063–e1067.
10.1016/j.clgc.2017.07.008
PubMed Web of Science® Google Scholar
18Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, et al. Pathological downstaging and survival outcomes associated with neoadjuvant chemotherapy for variant histology muscle invasive bladder cancer. J Urol. 2021; 206: 924–932.
10.1097/JU.0000000000001855
PubMed Google Scholar
19Zhu Z, Xiao Y, Hu S, Wang Z, Zhu Z. Neoadjuvant and adjuvant chemotherapy for variant histology bladder cancers: a systematic review and meta-analysis. Front Oncol. 2022; 12:907454.
10.3389/fonc.2022.907454
CAS PubMed Google Scholar
20Abufaraj M, Foerster B, Schernhammer E, Moschini M, Kimura S, Hassler MR, et al. Micropapillary urothelial carcinoma of the bladder: a systematic review and meta-analysis of disease characteristics and treatment outcomes. Eur Urol. 2019; 75: 649–658.
10.1016/j.eururo.2018.11.052
PubMed Web of Science® Google Scholar
21Meeks JJ, Taylor JM, Matsushita K, Herr HW, Donat SM, Bochner BH, et al. Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer. BJU Int. 2013; 111: E325–E330.
10.1111/j.1464-410X.2012.11751.x
PubMed Web of Science® Google Scholar
22von Landenberg N, Speed JM, Trinh QD. Do micropapillary patients benefit from chemotherapy? BJU Int. 2017; 119: 656–658.
10.1111/bju.13780
PubMed Web of Science® Google Scholar
23Mally AD, Tin AL, Lee JK, Satasivam P, Cha EK, Donat SM, et al. Clinical outcomes of patients with T1 nested variant of urothelial carcinoma compared to pure urothelial carcinoma of the bladder. Clin Genitourin Cancer. 2017; 16: e23–e27.
10.1016/j.clgc.2017.07.002
Google Scholar
24Kaushik D, Frank I, Boorjian SA, Cheville JC, Eisenberg MS, Thapa P, et al. Long-term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder. Int J Urol. 2015; 22: 549–554.
10.1111/iju.12729
PubMed Web of Science® Google Scholar
25Moschini M, Shariat SF, Freschi M, Soria F, D'Andrea D, Abufaraj M, et al. Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study. Urol Oncol. 2017; 35: e1–e5.
10.1016/j.urolonc.2017.03.024
PubMed Google Scholar
26La Croce G, Naspro R, Finati M, Pellucchi F, Sodano M, Manica M, et al. The accuracy of transurethral bladder resection in detecting bladder cancer histological variants and their prognostic value at radical cystectomy. J Clin Med. 2022; 11(3):550.
10.3390/jcm11030550
PubMed Google Scholar
27Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the bladder cancer research consortium. J Urol. 2006; 176: 2414–2422.
10.1016/j.juro.2006.08.004
PubMed Web of Science® Google Scholar
28Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol. 2001; 19: 666–675.
10.1200/JCO.2001.19.3.666
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume32, Issue5

May 2025

Pages 508-515

Filename	Description
iju15683-sup-0001-FileS1.pngPNG image, 748.8 KB	File S1.
iju15683-sup-0002-FileS2.pngPNG image, 738.2 KB	File S2.

The effect of neoadjuvant chemotherapy on survival outcomes in patients with variant histologies who underwent radical cystectomy with precystectomy diagnostic accuracy: A multicenter study of the Turkish Urooncology Association

Abstract

Objectives

Methods

Results

Conclusion

CONFLICT OF INTEREST STATEMENT

Supporting Information

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

The effect of neoadjuvant chemotherapy on survival outcomes in patients with variant histologies who underwent radical cystectomy with precystectomy diagnostic accuracy: A multicenter study of the Turkish Urooncology Association

This article relates to:

Comments on “The Effect of Neoadjuvant Chemotherapy on Survival Outcomes in Patients With Variant Histologies Who Underwent Radical Cystectomy With Precystectomy Diagnostic Accuracy: A Multicenter Study of the Turkish Urooncology Association”

Abstract

Objectives

Methods

Results

Conclusion

CONFLICT OF INTEREST STATEMENT

Supporting Information

REFERENCES

Citing Literature

References

Related

Information